Novel phosphate–phosphonate hybrid nanomaterials applied to biology by Bujoli, Bruno et al.
Novel phosphate–phosphonate hybrid nanomaterials
applied to biology
Bruno Bujoli, He´le`ne Roussie`re, Gilles Montavon, Samia La¨ıb, Pascal Janvier,
Bruno Alonso, Franck Fayon, Marc Petit, Dominique Massiot, Jean-Michel
Bouler, et al.
To cite this version:
Bruno Bujoli, He´le`ne Roussie`re, Gilles Montavon, Samia La¨ıb, Pascal Janvier, et al.. Novel
phosphate–phosphonate hybrid nanomaterials applied to biology. Progress in Solid State
Chemistry, Elsevier, 2006, 34, pp.257-266. <10.1016/j.progsolidstchem.2005.11.039>. <hal-
00022455>
HAL Id: hal-00022455
https://hal.archives-ouvertes.fr/hal-00022455
Submitted on 30 Nov 2006
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Novel phosphate-phosphonate hybrid nanomaterials, applied to biology  
 
Bruno Bujoli,a* Hélène Roussière,a,b Gilles Montavon,c Samia Laïb,a Pascal Janvier,a 
Bruno Alonso,d Franck Fayon,d Marc Petit,a Dominique Massiot,d Jean-Michel 
Bouler,b* Jérôme Guicheux,b Olivier Gauthier,b Sarah M. Lane,e Guillaume 
Nonglaton,a Muriel Pipelier,a Jean Léger,f Daniel R. Talham,e and Charles Tellierg  
aLaboratoire de Synthèse Organique, Université de Nantes, UMR CNRS 6513 and FR 
CNRS 2465, 2 Rue de la Houssinière , BP92208, 44322 Nantes Cedex 3, France. 
bMatériaux d’Intérêt Biologique, Université de Nantes, EM INSERM 99-03, Faculté 
de Chirurgie Dentaire, BP84215, 44042 Nantes Cedex 1, France. c Laboratoire de 
Physique Subatomique et des Technologies Associées, UMR CNRS 6457, Ecole des 
Mines de Nantes, 4 Rue Alfred KASTLER, BP 20722, 44307 Nantes Cedex 03, 
France. dCRMHT, UPR CNRS 4212, 1D Avenue de la Recherche Scientifique, 45071 
Orléans Cedex 02, France. eDepartment of Chemistry, University of Florida, 
Gainesville, Florida, 32611-7200, USA. fU INSERM 533, Université de Nantes, UFR 
de Médecine Physiologie, 1 rue Gaston Veil, BP 53508, 44035 NANTES Cedex 1, 
France. gLaboratoire de Biotechnologies, Biocatalyse Biorégulation, Université de 
Nantes, UMR CNRS 6204, 2 Rue de la Houssinière , BP92208, 44322 Nantes Cedex 
03, France. 
bruno.bujoli@chimie.univ-nantes.fr 
 
Abstract 
A new process for preparing oligonucleotide arrays is described that uses surface 
grafting chemistry which is fundamentally different from the electrostatic adsorption 
and organic covalent binding methods normally employed. Solid supports are 
modified with a mixed organic/inorganic zirconium phosphonate monolayer film 
providing a stable, well-defined interface.  Oligonucleotide probes terminated with 
phosphate are spotted directly to the zirconated surface forming a covalent linkage.  
Specific binding of terminal phosphate groups with minimal binding of the internal 
phosphate diesters has been demonstrated. On the other hand, the reaction of a 
bisphosphonate bone resorption inhibitor (Zoledronate) with calcium deficient 
hydroxyapatites (CDAs) was studied as a potential route to local drug delivery 
systems active against bone resorption disorders. A simple mathematical model of the 
Zoledronate / CDA interaction was designed that correctly described the adsorption of 
Zoledronate onto CDAs. The resulting Zoledronate-loaded materials were found to 
release the drug in different phosphate-containing media, with a satisfactory 
agreement between experimental data and the values predicted from the model. 
Introduction 
While research at the frontier between Chemistry and Biology is of major importance 
for the design of new drugs, there is also high potential for developing novel 
nanomaterials for biotechnology. In this context, metal phosphonate chemistry can be 
applied to the synthesis of biomaterials. Indeed, it is well known that phosphonic 
acids can react with various inorganic precursors, including metal salts or oxides or 
alkoxides, in organic or aqueous solution, leading to organic-inorganic hybrid 
networks [1].The key feature is the formation of metal-oxygen bonds, that can be 
highly covalent depending on the nature of the metal. Our idea was to modify 
inorganic surfaces (phosphonates, phosphates, oxides…) by coordination of the metal 
cations present on the surface, using phosphonic acids having various biological 
properties (Figure 1). 
In a first example, we will report a new support for the preparation of DNA arrays, in 
which the biological probes are bound to a monolayer-coated surface through an 
“inorganic” linkage, in contrast to existing systems based on the attachment of the 
probes via organic bonding. A second example will describe a novel drug delivery 
system, based on the chemical grafting of a gem-bisphosphonate monolayer on 
various calcium phosphates. 
 
Results and discussion 
1. Metal phosphonates as novel supports for the preparation of 
oligonucleotide microarrays 
DNA arrays have emerged as a convenient tool in molecular biological 
research, for rapid and accurate gene mapping, DNA sequencing, mRNA expression 
analysis, and diagnosis of genetic diseases [2,3]. Typical sensors consist either of 
double-stranded products (PCR) or single-stranded oligonucleotides of different 
sequences, called probes, bound to a surface and amenable to subsequent 
hybridization by targets. A popular approach to microarrays involves “spotting” 
techniques that use automated robots to array oligonucleotides previously synthesized 
by chemical or enzymatic methods. Glass substrates are preferred for arrays, since it 
is flat and non-porous, and so hybridization volume can be kept to a minimum, and it 
is durable under the temperatures and chemical conditions normally employed.  
Furthermore, the low fluorescence of glass does not significantly contribute to 
background noise when fluorescence is used for detection.  However, 
oligonucleotides bind poorly to glass, so some surface derivatization is required. The 
current trend is to form a surface bound monolayer of functional groups that are 
available to react only with a specific group on the probe terminus, resulting in 
covalent linkage. Organosilane-coating protocols are commonly used to fix the active 
groups to the glass surface (Figure 2). Some combinations of surface/oligonucleotide 
function that have been demonstrated include thiol/acrylamide [4], activated 
carboxylic acid/amine [5,6], amine/aldehyde [7-9], epoxide/amine [10], 
aldehyde/oxyamine [11]. 
Our purpose was to propose a fundamentally different route for covalently 
attaching DNA probes to surfaces for array applications. The new approach uses a 
mixed organic/inorganic monolayer to derivatize the glass and generate a reactive 
surface (Figure 3), using the Langmuir Blodgett (LB) technique. The LB process 
begins with an octadecylphosphonic acid (ODPA) Langmuir monolayer that is 
deposited onto the hydrophobic solid support in such a way that the hydrophilic acid 
group (PO3H2) is directed away from the support [12,13]. The substrate is then 
removed from the LB trough and exposed to a solution of Zr4+ ions that bind to give a 
monolayer of the zirconated octadecylphosphonic acid (ODPA-Zr).  In zirconium 
phosphonates, each Zr4+ ion coordinates to more than one phosphonate molecule and 
the phosphonates bind to more than one metal ion.  Therefore, the extremely strong 
binding of the zirconium ions crosslinks the original monolayer and provides a stable, 
well-defined interface of zirconium phosphonate sites [12,13]. The ODPA-Zr 
monolayer sticks strongly to the surface because it is no longer a traditional LB film 
of individual molecules physisorbed to the surface, but rather a network or monolayer 
tape where adhesion comes from the sum of all molecules in a crosslinked array.  The 
ODPA-Zr monolayers can be stored in water for months and retain activity with no 
evidence of desorption. The metal ions now on the surface are active and react readily 
when exposed to other phosphonic acids or organophosphates to bind them to the 
surface (Figure 1). For example, in a recent study, we used these surfaces to bind 
monolayers of a phosphorylated manganese porphyrin oxidation catalyst and studied 
organic transformations at the monolayer with no desorption of the film, permitting 
detailed studies of a surface-confined molecular catalyst [14].  
The coordination properties of free phosphate (OPO3H2) are very close to 
those of the phosphonic acid function, and phosphate species graft similarly to 
zirconium phosphonate surfaces. As phosphate is a naturally occurring function that 
does not alter the intrinsic nature of the probe, and that can be introduced chemically 
or with enzymatic routes, we have used such nucleotides to build microarrays on the 
ODPA-Zr surfaces (Figure 4) using commercially available arrayers and scanners for 
the printing and imaging steps. 
High specificity of the oligonucleotide anchoring onto the support has been 
demonstrated, along with good sensitivity of the resulting immobilized probes for 
detecting complementary targets [15]. Although not yet investigated, the methodology 
should be readily adapted to iono-covalent anchoring of phosphorylated double-
stranded DNA prepared by PCR, a process that is harder with the more common 
organic covalent anchoring mechanisms because they require non-natural 
modification of the probes. While not required, improved signal-to-noise ratio is 
obtained by post-spotting treatment with BSA (Bovine Serum Albumin) to passivate 
the unspotted regions of the arrays.  Signal-to-noise ratios as high as 1000 have been 
demonstrated after hybridizing with fluorescent targets.  The BSA treatment displaces 
physisorbed probes and protects the array from nonspecific binding of targets.  The 
BSA also provides a biocompatible hydrophilic surface.  Further improvements in 
performance were observed when the probe is linked to the terminal phosphate via a 
spacer.  Oligomeric guanine spacers of 7-11 units were found to be optimal, while 
polyA, polyC, and polyT spacers did not show the same enhancement (Figure 5) 
[15,16]. 
2. Metal phosphonate-based drug delivery systems active against bone 
resorption disorders 
It is easy to imagine that the idea of interfacing mixed organic/inorganic 
interfaces can be extended to other applications. The concept of using the 
coordinating abilities of phosphate or related phosphonic acid groups towards metal 
ions on inorganic surfaces can also be extended to other bio-technology problems.  
One example is the design of better drug delivery systems that could reduce side 
effects, improve efficacy of existing drugs and open the door to entire classes of new 
treatments. Given that the strength of the interaction between the phosphate or 
phosphonate and the metal support can be tuned by changing the nature of the metal 
center, the immobilization of therapeutic agents that naturally bear such functional 
groups onto inorganic biocompatible carriers could offer great potential in the field of 
medical devices. In this context, calcium phosphate ceramics [CaPs], commonly used 
as implants for bone reconstruction [17,18] appear to be good candidates, since they 
can be resorbed by bone cells. For example, we were able to chemically combine 
CaPs with a geminal bisphosphonate (Zoledronate) [19,20] that is efficient for the 
treatment of post-menopausal osteoporosis [21] and bone metastases [22] (Figure 6). 
Indeed, we have shown that CDAs (calcium deficient apatites) undergo chemisorption 
of the drug through a surface adsorption process, due to PO3 for PO4 exchange 
(Figure 6) [19,20]. A simple mathematical model was designed, that correctly 
described the Zoledronate / CDAs interaction at equilibrium as Equation (1) (Figure 
7), in simplified media such as ultrapure water or phosphate buffers [23]:  
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where X≡ corresponds to the surface binding sites of the CDA that must be in 
interaction with either a Zoledronate (Z) or a phosphate (P) moiety. 
It was noticed that for a given phosphate concentration and a given solid/liquid 
ratio, the Zoledronate concentration released in solution decreased for decreasing Γ 
bisphosphonate loading ratios. This suggests that the therapeutic effect (i.e. the 
amount of Zoledronate released in the medium) might be tuned according to the initial 
value of Γ. Furthermore, in spite of the complex composition of a culture medium, 
containing an important number of potentially competing species for Zoledronate, our 
simple model allowed to predict the Zoledronate release in simulated in vitro 
conditions. This clearly indicated that the phosphate concentration is the main 
parameter governing Zoledronate desorption when sorbed onto CDAs. The ability of 
the resulting biomaterials to release the bisphosphonate drug was demonstrated using 
in vitro studies [20], and in a recent in vivo experiment, we were able to establish the 
proof of concept for apatitic materials used as drug delivery systems. The local 
bisphosphonate release from an apatitic calcium phosphate coating allowed to 
increase the mechanical fixation of an orthopedic implant (Figure 8) [24]. Obviously 
the increase in peri-implant bone density appeared to be dependent on the Zoledronate 
content of the coating. The potential of this type of biomaterial to stabilize newly 
formed bone tissue in osteoporotic implantation sites is currently under investigation.  
 
 
Conclusion 
In the present paper, we have described that inorganic surfaces can be modified by 
coordination of metal cations present on the surface, using phosphonic acids or 
closely related phosphate compounds, having various biological properties. The 
resulting organic-inorganic hybrid materials can be applied to biology.  In a first 
example, we have reported a new approach for covalently immobilizing 
oligonucleotides on glass slides for microarray applications that takes advantage of 
mixed organic/inorganic zirconium phosphonate chemistry. On the other hand, we 
have shown that one type of gem-bisphosphonate, Zoledronate, a potent inhibitor for 
bone resorption, can be chemically associated onto calcium deficients apatites 
(CDAs). The ability of such materials to release Zoledronate suggests that they could 
be used as local bisphosphonate delivery systems, active against osteoporosis. 
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List of figure captions 
 
Figure 1. Schematic representation of the modification of inorganic surfaces for the 
preparation of biologically active materials. 
 
Figure 2. Scheme illustrating covalent immobilization of oligonucleotide probes, 
using organo-silane coating protocols. 
 
Figure 3. Langmuir-Blodgett route to zirconated phosphonate modified slides.  a.  In 
step 1, a monolayer of octadecylphosphonic acid (ODPA) is deposited onto a 
hydrophobic slide (here, made hydrophobic with octadecyltrichlorosilane, OTS).  In 
step 2, the slide is then exposed to a solution of Zr4+(aq).  The slide can then be rinsed 
and used immediately or stored in water for months before use.  b.  the zirconated 
ODPA slides are very smooth (right), compared here to the OTS covered glass before 
deposition (left). 
 
Figure 4. Organic/inorganic surfaces for DNA arrays. Phosphate terminated probes 
attach specifically via coordinate covalent bonding (bonds are left out of the figure for 
clarity) to a zirconated phosphonic acid modified surface. 
 
Figure 5. Fluorescence enhancement upon hybridization with labeled target related to 
the introduction of a polyG spacer to the probe. The effect is present for different 
probes (sequence X, Y or Z) spotted at different concentrations. The slides were 
spotted with  5’H2O3PO-(B)11-O33 and hybridized with 100 nM complements comp-
5’CY3-O33, where O33 corresponds to a 33mer oligonucleotide (sequence X, Y or 
Z). 
 Figure 6.Schematic representation of the chemical association of Zoledronate onto 
CDAs (left). 31P 2D SC14 Single Quantum-Double Quantum (SQ-DQ) NMR 
correlation spectrum obtained for a Zoledronate-loaded CDA(NaOH) sample [Γ = 
0.97]. For clarity, the 2D data set is presented as a homonuclear SQ-SQ correlation 
(shearing transformation of the vertical DQ dimension). The 31P 1D spectrum on the 
top is the projection of the SC14 2D spectrum on the horizontal SQ axis, that is fully 
similar to the 31P Cross-Polarisation 1D spectrum obtained using the same contact 
time. Off-diagonal cross-peaks are identified by grey arrows. The 2D correlation 
spectrum shows clearly the presence of off-diagonal cross-correlation peaks between 
the Zoledronate and CDA resonances giving evidence of the spatial proximity 
between the phosphorus sites of the two compounds. The low intensity of these peaks 
is in agreement with a chemisorption process that only occurs on the surface of the 
CDA granules, thereby leaving the bulk of the phosphate groups away from 
Zoledronate.  
 
Figure 7. Zoledronate / CDA(NH3) (filled symbols) or CDA(NaOH) (open symbol) 
interaction study of in phosphate buffers. (A): Sorption isotherms measured as a 
function of the Solid/Liquid ratio in the 0.25 to 200 g/L range. (B) Percentage of 
Zoledronate desorbed as a function of the phosphate concentration introduced in 
solution. (C) Zoledronate released as a function of the Zoledronate loading ratio Γ. 
[P]tot = 0.25 mol/L, S/L = 1 g/L. The lines correspond to calculated values according 
to Equation (1) (solid line: CDA(NH3); dotted line: CDA(NaOH)). Zoledronate 
concentrations were analyzed by Total Organic Carbon (TOC) measurements or by 
liquid scintillation counting when 14C-labeled Zoledronate was used. CDA(NH3) and 
CDA(NaOH) were obtained by alkaline hydrolysis of dicalcium phosphate dihydrate 
(DCPD), using aqueous ammonia or sodium hydroxide, respectively. 
 
Figure 8. SEM pictures of two implanted rat condyles. Panel (a) shows the bone 
structure of a condyle implanted with a coated implant containing 2 µg Zoledronate 
(top) and the peri-implant bone (bottom), at magnification of 10X and 23X, 
respectively. Panel (b) shows the same views for a coated implant containing no 
Zoledronate. 
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